Aram Andrew Mangasarian
Amministratore Delegato presso TME PHARMA N.V.
Posizioni attive di Aram Andrew Mangasarian
Società | Posizione | Inizio | Fine |
---|---|---|---|
TME PHARMA N.V. | Amministratore Delegato | 01/05/2010 | - |
Corporate Officer/Principal | 01/05/2010 | - | |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Direttore/Membro del Consiglio | 01/05/2010 | - |
Amministratore Delegato | 01/05/2010 | - | |
Corporate Officer/Principal | 19/05/2010 | 24/07/2015 | |
NOXXON Pharma NV Niederlassung Deutschland
NOXXON Pharma NV Niederlassung Deutschland BiotechnologyHealth Technology NOXXON Pharma NV Niederlassung Deutschland operates as a German biotechnology company. The private company is based in Berlin, Germany. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Aram Andrew Mangasarian
Precedenti posizioni note di Aram Andrew Mangasarian
Società | Posizione | Inizio | Fine |
---|---|---|---|
ISOFOL MEDICAL AB | Direttore/Membro del Consiglio | 01/06/2020 | 01/02/2023 |
Independent Dir/Board Member | 01/06/2020 | 01/02/2023 | |
EUROBIO SCIENTIFIC | Corporate Officer/Principal | - | - |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Corporate Officer/Principal | 01/05/2000 | - |
Caerus Consulting AS
Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Direttore/Membro del Consiglio | - | - |
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Corporate Officer/Principal | 01/10/2005 | - |
Formazione di Aram Andrew Mangasarian
INSEAD | Masters Business Admin |
University of California San Diego | Doctorate Degree |
University of Wisconsin | Undergraduate Degree |
Statistiche
Distribuzione geografica
Francia | 5 |
Germania | 4 |
Stati Uniti | 3 |
Posizioni
Corporate Officer/Principal | 5 |
Director/Board Member | 4 |
Chief Executive Officer | 2 |
Settori
Health Technology | 9 |
Consumer Services | 4 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
TME PHARMA N.V. | Health Technology |
EUROBIO SCIENTIFIC | Health Technology |
ISOFOL MEDICAL AB | Health Technology |
Aziende private | 5 |
---|---|
Novexel SA
Novexel SA Pharmaceuticals: MajorHealth Technology Novexel SA researches and develops anti-infective drugs for the treatment of bacterial and fungal infections. The firm focuses on discovery and development of novel antibiotics designed to overcome the significant global problem of microbial resistance. The company was founded in December 2004 and is headquartered in Romainville, France. | Health Technology |
Exonhit
Exonhit Pharmaceuticals: MajorHealth Technology Exonhit is developing and manufacturing novel pharmaceuticals from its expertise in the field of alternative RNA splicing, the process by which a single gene can lead to several proteins. The firm's proprietary gene profiling technology DATAS is utilized to identify genes whose splice variants produce abnormal proteins which may trigger or contribute to the development of disease. The company was founded in 1997 and is headquartered in Paris, France. | Health Technology |
NOXXON Pharma AG
NOXXON Pharma AG BiotechnologyHealth Technology NOXXON Pharma AG operates a clinical stage biotechnology company. Its core focus is on cancer treatment. The firm offers effectiveness of cancer treatments including immuno-oncology approaches such as immune checkpoint inhibition and current standards of care such as chemotherapy and radiotherapy. The company was founded in 1997 by Sven Klussmann, Jens-Peter Fürste and Thomas Klein and is headquartered in Berlin, Germany. | Health Technology |
Caerus Consulting AS
Caerus Consulting AS Pharmaceuticals: MajorHealth Technology Caerus Consulting AS engages in the research and development in biotechnology. It develops antibiotics for life threatening bacterial diseases. Its technological core is chemistry on complex molecules. The company was founded by Torgeir Vaage on March 31, 2009 and is headquartered in Hovik, Norway. | Health Technology |
NOXXON Pharma NV Niederlassung Deutschland
NOXXON Pharma NV Niederlassung Deutschland BiotechnologyHealth Technology NOXXON Pharma NV Niederlassung Deutschland operates as a German biotechnology company. The private company is based in Berlin, Germany. | Health Technology |